Limits...
Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial.

Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A - J Pharmacol Pharmacother (2013)

Bottom Line: There was no significant difference between mean reductions in FPG in both the groups.Both the treatment groups reported a significant decrease in High-density lipoprotein (HDL-C) and Triglyceride.It was concluded that sitagliptin as an add-on to metformin is as effective and well tolerated as pioglitazone.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Maulana Azad Medical College, New Delhi, India.

ABSTRACT

Objective: To compare and study the dipeptidy1 peptidase-4 (DPP-4) inhibitors in combination with metformin against established combination therapies.

Materials and methods: This 16-week study was designed to compare sitagliptin versus pioglitazone as add-on therapy in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Fifty-two patients were randomized into two groups to receive either sitagliptin 100 mg (group 1) or pioglitazone 30 mg (group 2) in addition to metformin. The primary efficacy end point was change in HbA1c. Secondary end points included change in fasting plasma glucose (FPG), body weight and lipid profile. Treatment satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire. Both the groups had a significant decrease in HbA1c.

Results: There was no significant difference between mean reductions in FPG in both the groups. There was a significant decrease in the mean body weight and body mass index in group 1 in contrast to the significant increase in the same in group 2. Both the treatment groups reported a significant decrease in High-density lipoprotein (HDL-C) and Triglyceride.

Conclusion: Sitagliptin was well tolerated without any incidence of hypoglycemia. It was concluded that sitagliptin as an add-on to metformin is as effective and well tolerated as pioglitazone.

No MeSH data available.


Related in: MedlinePlus

Comparative mean weight change in both groups
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3643339&req=5

Figure 2: Comparative mean weight change in both groups

Mentions: A mean decrease of 0.58 kg was seen in treatment group 1 from a baseline mean weight of 72.1 ± 13.76 kg after 16 weeks, and this change was statistically significant. In contrast to this, subjects of group 2 had a mean increase of 0.90 kg in their weight from a baseline level of 72.68 ± 10.83 kg, which was also statistically significant [Figure 2].


Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial.

Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A - J Pharmacol Pharmacother (2013)

Comparative mean weight change in both groups
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3643339&req=5

Figure 2: Comparative mean weight change in both groups
Mentions: A mean decrease of 0.58 kg was seen in treatment group 1 from a baseline mean weight of 72.1 ± 13.76 kg after 16 weeks, and this change was statistically significant. In contrast to this, subjects of group 2 had a mean increase of 0.90 kg in their weight from a baseline level of 72.68 ± 10.83 kg, which was also statistically significant [Figure 2].

Bottom Line: There was no significant difference between mean reductions in FPG in both the groups.Both the treatment groups reported a significant decrease in High-density lipoprotein (HDL-C) and Triglyceride.It was concluded that sitagliptin as an add-on to metformin is as effective and well tolerated as pioglitazone.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Maulana Azad Medical College, New Delhi, India.

ABSTRACT

Objective: To compare and study the dipeptidy1 peptidase-4 (DPP-4) inhibitors in combination with metformin against established combination therapies.

Materials and methods: This 16-week study was designed to compare sitagliptin versus pioglitazone as add-on therapy in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Fifty-two patients were randomized into two groups to receive either sitagliptin 100 mg (group 1) or pioglitazone 30 mg (group 2) in addition to metformin. The primary efficacy end point was change in HbA1c. Secondary end points included change in fasting plasma glucose (FPG), body weight and lipid profile. Treatment satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire. Both the groups had a significant decrease in HbA1c.

Results: There was no significant difference between mean reductions in FPG in both the groups. There was a significant decrease in the mean body weight and body mass index in group 1 in contrast to the significant increase in the same in group 2. Both the treatment groups reported a significant decrease in High-density lipoprotein (HDL-C) and Triglyceride.

Conclusion: Sitagliptin was well tolerated without any incidence of hypoglycemia. It was concluded that sitagliptin as an add-on to metformin is as effective and well tolerated as pioglitazone.

No MeSH data available.


Related in: MedlinePlus